Novel Enteric Microsphere of Beclomethasone Dipropionate With Colon Delivery and Enhancement of Anti‐Inflammatory Effects
Biopharmaceutics & Drug Disposition · 2025
DOI: 10.1002/bdd.70005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biopharmaceutics & Drug Disposition, 2025. Verfasst von Atsushi Uchida und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Biopharmacy, School of Pharmaceutical Sciences, University of Shizuoka, Suruga-ku, Japan. Hauptthemen laut MEDLINE: Beclomethasone, Colon, Anti-Inflammatory Agents, Colitis, Ulcerative. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
The present study aimed to develop a novel colon‐targeting microsphere of beclomethasone dipropionate (cMS/BDP) with enhanced pharmacological effect of BDP in the colon. cMS/BDP was prepared using Eudragit ® S‐100 by the emulsion solvent diffusion method, and its physicochemical properties were characterized. A pharmacokinetic study was conducted to assess systemic exposure and colon distribution of BDP after oral administration of cMS/BDP to rats. A pharmacodynamic study was carried out to evaluate the anti‐inflammatory effect of cMS/BDP after its oral administration to ulcerative colitis model rats. The particle size of cMS/BDP was calculated to be ca. 20 μm, and most BDP in cMS/BDP might be in an amorphous state. In dissolution tests, cMS/BDP showed pH‐dependent release behavior of BDP and marked BDP release at pH 7.4. After oral administration of cMS/BDP (5 mg‐BDP/kg) to rats, BDP was rapidly metabolized to beclomethasone 17‐monopropionate (17‐BMP, a BDP metabolite) in the gastrointestinal tract and liver, and relative oral bioavailability of 17‐BMP in the cMS/BDP group was calculated to be ca. 4.8% compared with that in the BDP solution group. The tissue‐to‐plasma partition coefficient value, an index of colon distribution, for cMS/BDP was found to be 15‐fold higher than that for BDP solution. In the cMS/BDP (50 μg/kg) group, colonic myeloperoxidase activity and hyperplasia of the submucosa were negligibly elevated. From these findings, the cMS approach for BDP would be a promising dosage option for strategic colon delivery, leading to an improved therapeutic potential of BDP with a wide safety margin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Biopharmacy, School of Pharmaceutical Sciences, University of Shizuoka, Suruga-ku, Japan.
- Department of Pharmacy, University of Yamanashi Hospital, Chuo-city, Japan.
ORCID-Profile: Atsushi Uchida
Zitieren
APA
Uchida, A., Hayashi, Y., Kihara, T., Yamada, K., Sato, H., & Onoue, S. (2025). Novel Enteric Microsphere of Beclomethasone Dipropionate With Colon Delivery and Enhancement of Anti‐Inflammatory Effects. Biopharmaceutics & Drug Disposition. https://doi.org/10.1002/bdd.70005
Vancouver
Uchida A, Hayashi Y, Kihara T, Yamada K, Sato H, Onoue S. Novel Enteric Microsphere of Beclomethasone Dipropionate With Colon Delivery and Enhancement of Anti‐Inflammatory Effects. Biopharmaceutics & Drug Disposition. 2025. doi:10.1002/bdd.70005
BibTeX
@article{Uchida2025,
author = {Uchida, Atsushi and Hayashi, Yuto and Kihara, Tsubasa and Yamada, Kohei and Sato, Hideyuki and Onoue, Satomi},
title = {Novel Enteric Microsphere of Beclomethasone Dipropionate With Colon Delivery and Enhancement of Anti‐Inflammatory Effects},
journal = {Biopharmaceutics & Drug Disposition},
year = {2025},
doi = {10.1002/bdd.70005}
}
EUVIMED